In February 2014, Sales & Marketing Director Philip Ridley-Smith, attended the UKTI Japan (UK Trade & Investment) Life Sciences Mission for Oncology in Tokyo.
Cancer has been the leading cause of death in Japan since the 1980s and the government takes this very seriously, bringing in the 2007 Cancer Control Act to improve the situation and spending a total of £2.4bn. Both the pharmaceutical and healthcare industries regard cancer as one of the core therapeutic areas with high demands for innovative technology licensing and product imports.
The biotechnology and pharmaceutical industry in Japan is the world’s second largest; at 12% of the global market, it is bigger than France and Germany combined. Japan has a number of pharmaceutical research companies operating on a global basis and the market for biologics such as antibodies, protein based drugs and vaccines is increasing.
The UKTI event provided a fantastic opportunity to network and conduct one-to-one meetings with both prospective and existing Japanese customers; presenting Cobra's one-stop-shop manufacturing services offering.
A short video of Philip Ridley-Smith's conference presentation, 'Manufacturing Oncology Products: A Guide to Outsourcing Success', can be found on YouTube.